HomeCompareAEZS vs SBUX

AEZS vs SBUX: Dividend Comparison 2026

AEZS yields 34.97% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AEZS wins by $8.5K in total portfolio value
10 years
AEZS
AEZS
● Live price
34.97%
Share price
$5.72
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$175.6K
Annual income
$26,494.15
Full AEZS calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — AEZS vs SBUX

📍 AEZS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAEZSSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AEZS + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AEZS pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AEZS
Annual income on $10K today (after 15% tax)
$2,972.03/yr
After 10yr DRIP, annual income (after tax)
$22,520.03/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $37,945.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AEZS + SBUX for your $10,000?

AEZS: 50%SBUX: 50%
100% SBUX50/50100% AEZS
Portfolio after 10yr
$171.3K
Annual income
$48,815.30/yr
Blended yield
28.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

AEZS
Analyst Ratings
4
Buy
2
Hold
1
Sell
Consensus: Buy
Altman Z
0.3
Piotroski
1/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AEZS buys
0
SBUX buys
0
No recent congressional trades found for AEZS or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAEZSSBUX
Forward yield34.97%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$175.6K$167.0K
Annual income after 10y$26,494.15$71,136.45
Total dividends collected$126.6K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: AEZS vs SBUX ($10,000, DRIP)

YearAEZS PortfolioAEZS Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$14,197$3,496.50$11,121$420.68+$3.1KAEZS
2$19,829$4,639.08$12,548$648.40+$7.3KAEZS
3$27,273$6,055.84$14,440$1,013.98+$12.8KAEZS
4$36,967$7,784.29$17,068$1,617.30+$19.9KAEZS
5$49,415$9,860.73$20,912$2,649.52+$28.5KAEZS
6$65,193$12,318.97$26,875$4,499.29+$38.3KAEZS
7$84,946$15,189.12$36,771$8,014.12+$48.2KAEZS
8$109,388$18,496.47$54,542$15,197.11+$54.8KAEZS
9$139,306$22,260.50$89,602$31,242.49+$49.7KAEZS
10$175,552$26,494.15$167,011$71,136.45+$8.5KAEZS

AEZS vs SBUX: Complete Analysis 2026

AEZSStock

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Full AEZS Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this AEZS vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AEZS vs SCHDAEZS vs JEPIAEZS vs OAEZS vs KOAEZS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.